There are 2789 resources available
LBA22 - Neoadjuvant chemotherapy with oxaliplatin and capecitabine versus chemoradiation with capecitabine for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Initial results of a multicenter randomised, open-label, phase III trial
Presenter: Pei-Rong Ding
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Slides
Webcast
385O - Automated detection of microsatellite status in early colon cancer (CC) using artificial intelligence (AI) integrated infrared (IR) imaging on unstained samples from the AIO ColoPredictPlus 2.0 (CPP) registry study
Presenter: Frederik Großerüschkamp
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Slides
Webcast
825O - Ivosidenib in Chinese patients (pts) with relapsed/refractory acute myeloid leukemia (R/R AML) with an IDH1 mutation: Results from a bridging registrational study
Presenter: Mingyuan Sun
Session: Proffered Paper session - Haematological malignancies
Resources:
Abstract
Slides
Webcast
826O - Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the phase III CHRONOS-3 trial
Presenter: Muhit Özcan
Session: Proffered Paper session - Haematological malignancies
Resources:
Abstract
Slides
Webcast
LBA35 - Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial
Presenter: Jean Bourhis
Session: Proffered Paper session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
LBA47 - Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial
Presenter: Benjamin Besse
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Abstract
Slides
Webcast
1281O - Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C
Presenter: Rafal Dziadziuszko
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Abstract
Slides
Webcast
LBA48 - DUBLIN-3 (BPI-2358-103): A global phase (Ph) III trial with the plinabulin/docetaxel (Plin/Doc) combination vs. Doc in 2nd/3rd Line NSCLC patients (pts) with EGFR-wild type (wt) progressing on a prior platinum-based regimen
Presenter: Trevor Feinstein
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Abstract
Slides
Webcast
1191O - MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
Presenter: Ticiana Leal
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Abstract
Slides
Webcast
1502O - OncoYoung program: A multidisciplinary program for young cancer patients
Presenter: Irit Ben-Aharon
Session: Proffered Paper session - Public policy
Resources:
Abstract
Slides
Webcast